โ† All drugs

Drug companion protocol

Cagrilintide

Prescription only
Amylin analogue

Also known as: CagriSema (combination)

A long-acting amylin analogue under clinical investigation for weight management, including in combination with semaglutide.

Quickstart Highlights

Drug class
Amylin analogue
Route
Subcutaneous injection
Schedule
Weekly subcutaneous injection
Evidence score
45

Quickstart highlights

  • ๐Ÿ’‰Subcutaneous injection
  • ๐Ÿ”ฌAmylin analogue
  • ๐Ÿ“‹Prescription required

How this works

Mechanism of action and pharmacokinetic profile from published data.

Cagrilintide is a long-acting analogue of amylin โ€” a hormone co-secreted with insulin from pancreatic beta-cells. Amylin slows gastric emptying, suppresses post-meal glucagon secretion, and signals satiety in the brain via area postrema receptors โ€” a complementary pathway to GLP-1 agonism. Because amylin and GLP-1 work through different pathways, combining cagrilintide with semaglutide (as "CagriSema") may produce additive weight loss beyond either agent alone. Phase 2 data support this hypothesis; Phase 3 trials are ongoing.

Time to peak (Tmax)
~3โ€“4 days after subcutaneous injection.
Clearance
Degraded via proteolytic pathways โ€” specific clearance data from published Phase 2 trials.
Elimination half-life
Approximately 7 days, supporting once-weekly subcutaneous dosing (reported from Phase 1/2 data).
Bioavailability
Data from investigational Phase 2 studies; not yet on a product label.

Clinical Benefits & Side Effects

Observed outcomes, adverse effects, and lifecycle considerations from published trial data.

Benefits

Week 0

Starting in a trial context

Cagrilintide is only available in clinical trials as of 2024โ€“2025. It has been studied primarily as part of the CagriSema combination (with semaglutide). The dose-escalation protocols vary by trial.

Week 1

First injection โ€” taking the first step

This is your first week, and just starting is something to feel good about. You may not notice much physically yet โ€” that's completely normal at this early, low dose. Some people feel mild nausea or a reduced appetite, while others feel little to nothing different.

Week 2

Body beginning to adjust to the medication

Your body is still getting used to cagrilintide, and side effects like mild nausea, reduced appetite, or tiredness may come and go. Don't be discouraged if you don't see changes on the scale โ€” the early weeks are about building a foundation, not dramatic results.

Week 3

Navigating early side effects with more confidence

By now you may have developed a feel for how your body responds around injection day. Nausea, if present, often peaks within the first day or two after your injection and then eases. Small, frequent meals and staying well hydrated can make a real difference this week.

Week 4

Completing your first month โ€” building consistency

Reaching four weeks is a genuine milestone โ€” consistency now is laying the groundwork for everything ahead. Many people are still in a low-dose adjustment phase and haven't seen major weight changes yet, and that's expected. Focus on locking in good habits around food, hydration, and movement.

Week 5

Dose may increase โ€” appetite changes become clearer

If your prescriber has scheduled a dose increase, you may notice appetite suppression becoming more noticeable this week. Some people find they feel satisfied with smaller portions almost without trying โ€” lean into that, but make sure you're still eating enough nutritious food.

Week 6

Appetite suppression making meals feel different

Food may feel less urgent or less exciting than it used to โ€” this is the medication working as intended. It's a good time to focus on eating slowly and mindfully, so you can tune in to your body's genuine hunger and fullness signals. Side effects often start to ease as your body adapts.

Week 7

Finding a rhythm with food and movement

Many people start to feel more settled this week and find it easier to plan meals and stay active. If nausea has been a challenge in earlier weeks, you may notice it's becoming more manageable. This is a great time to build or strengthen a gentle exercise habit.

Side effects

โ—ฆNausea(mild-to-moderate)

More frequent in the CagriSema combination than either drug alone

โ—ฆConstipation(mild)

Reported

โ—ฆDiarrhoea(mild)

Reported

โ—ฆVomiting(mild)

Reported; more frequent in combination arm

Lifecycle factors

This is an investigational medicine

Cagrilintide is not commercially available. If you are reading this because you are participating in a trial, all questions about dose, protocol, and tolerability management should go to your trial site team โ€” not a community forum.

CagriSema GI burden is higher than either drug alone

In Phase 2 data, the combination of cagrilintide and semaglutide produced more GI adverse events than either drug alone, though most were mild-to-moderate. Dose escalation is typically slower to minimise this.

Manage nausea with simple, bland foods

If nausea hits, reach for foods that are gentle on the stomach: plain crackers, dry toast, banana, or plain white rice. Avoid skipping meals entirely when nauseous โ€” an empty stomach can actually make nausea worse. Cold or room-temperature foods are often better tolerated than hot, strongly-smelling dishes.

Keep a simple weekly log to share with your prescriber

A brief weekly note โ€” covering your weight, any side effects, energy levels, and how you're eating โ€” gives your prescriber valuable information to support and adjust your plan. It doesn't need to be detailed: even a note in your phone with a few dot points each week is enough. This log is also a powerful motivator when you look back and see how far you've come.

Important note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. All information presented is based on published clinical trial data. Always follow your prescriber's instructions.

Nutrition & practical guidance

Food, hydration, and adherence tips compiled from trial data and clinical companion content.

Food and hydration

โœ… Prefer

Lean protein (chicken breast, canned tuna, eggs, tofu)Low-GI wholegrains (rolled oats, brown rice, wholegrain bread)Lean protein-first eatingNon-starchy vegetables (zucchini, leafy greens, broccoli, cucumber)Non-starchy vegetablesPlain Greek yoghurt and low-fat dairySmall, frequent mealsSoft, easy-to-digest fruits (banana, tinned peaches in juice, rockmelon)

โš ๏ธ Limit

High-fat, fried foodsLarge portionsHigh-fat takeaway and fast food (burgers, hot chips, fried chicken)

โŒ Avoid

Alcohol

Adherence tips

administration

Rotate your injection sites consistently

Inject into the fatty tissue of your abdomen, thigh, or upper arm โ€” and rotate sites each week to avoid lumps or skin changes at any one spot. Keep a simple note on your phone or a sticky note to track where you injected last. Always follow your prescriber's instructions on exactly how and where to inject.

administration

Let your injection reach room temperature first

Take your cagrilintide out of the fridge **15โ€“30 minutes before** injecting. A cold injection can sting more and feel uncomfortable going in. Keep it out of direct sunlight while it warms up, and never try to heat it in a microwave or hot water.

timing

Pick a weekly injection day and stick to it

Choosing the same day each week โ€” for example, every Sunday morning โ€” makes it much easier to build the habit and reduces the chance of missing a dose. Set a recurring phone reminder with a label like 'Weekly injection day' so it becomes a non-negotiable part of your routine.

timing

Plan lighter meals around your injection day

Many people find that nausea is most noticeable in the 24โ€“48 hours after their injection. Try to schedule your injection day when you can eat gently โ€” think plain rice, scrambled eggs, or yoghurt โ€” rather than on a day with a big social meal or celebration planned.

nutrition

Protein intake supports the lean mass you want to preserve

Significant weight loss from any GLP-1 class drug can include lean mass loss. Adequate protein (1.2โ€“1.6 g/kg/day) and resistance exercise help preserve it.

hydration

Start every morning with a full glass of water

Before coffee, before scrolling your phone โ€” drink a full 250โ€“300 mL glass of water first thing in the morning. This jumpstarts your hydration for the day and can help ease morning nausea. Keep a water bottle visible on your kitchen bench as a prompt.

hydration

Sip, don't gulp โ€” especially when nauseous

Drinking large amounts of fluid quickly can worsen nausea and bloating. Instead, aim to sip water **little and often** throughout the day โ€” roughly 150โ€“200 mL every 30โ€“45 minutes. A marked water bottle or hydration app can help you track this without thinking too hard about it.

nutrition

Prioritise protein at every meal

When your appetite is reduced, every bite counts โ€” so make protein the centrepiece of your meals. Aim for at least **20โ€“30 g of protein per meal** from sources like eggs, Greek yoghurt, tinned fish, legumes, or chicken. Protein helps protect your muscle while your body adjusts, and it keeps you feeling fuller for longer.

nutrition

Eat smaller portions, more frequently

Rather than three large meals, try **4โ€“5 smaller meals or snacks** spread across the day. This works with the medication's effect on gastric emptying rather than against it, and reduces the chance of feeling uncomfortably full or nauseous after eating. A small meal might be half a cup of rolled oats with Greek yoghurt, or two boiled eggs on wholegrain toast.

exercise

Start with short, low-intensity walks

You don't need to hit the gym hard, especially in the early weeks. A **15โ€“20 minute walk** after dinner is a great starting point โ€” it aids digestion, supports blood sugar management, and improves mood. Gradually build toward 30 minutes most days as your energy and comfort allow. Even a stroll around the block counts.

exercise

Add light resistance training to protect muscle

As your body loses weight, including some resistance-based movement โ€” like bodyweight exercises, resistance bands, or light weights โ€” helps ensure you're maintaining muscle, not just losing it. Aim for **2 sessions per week** of 20โ€“30 minutes. You don't need a gym; exercises like wall sits, chair squats, and push-ups against a bench are a great start.

sleep

Protect your sleep โ€” it supports your progress

Poor sleep increases hunger hormones and cravings, which can work directly against the appetite-regulating effects of the medication. Aim for **7โ€“9 hours per night** and try to keep a consistent bedtime. If nausea is disrupting your sleep, speak with your prescriber โ€” there may be simple strategies that can help.

mindset

Measure progress beyond the scales

The number on the scale is just one data point, and it can fluctuate significantly from day to day due to fluid, food, and other factors. Keep a simple weekly note of **non-scale victories**: better energy, improved sleep, walking further without getting puffed, or clothes fitting differently. These are real signs of progress and worth celebrating.

mindset

Be patient and compassionate with yourself in early weeks

The first four weeks can genuinely be hard โ€” nausea, fatigue, and little visible change can feel discouraging. Remember that your body is adjusting to a new medication, and discomfort in these early weeks doesn't mean it isn't working. Reach out to your prescriber or a support person if you're struggling; you don't have to navigate this alone.

Safety and interactions

Share this information with your prescriber for personalised care decisions.

Who should not take this

Cagrilintide is investigational โ€” not yet approved by the TGA, FDA, MHRA, or EMA. Access is limited to clinical trials. Based on Phase 2 trial exclusion criteria and the amylin receptor class: โ€ข Existing amylin-pathway contraindications are not fully characterised โ€ข Trials have excluded participants with severe GI disease, active eating disorders, severe kidney or liver impairment, recent cardiovascular events, pregnancy, and breastfeeding No formal prescribing label exists. Speak with your trial site or prescriber for any questions about eligibility.

Known interactions

  • Insulin and insulin secretagogues
    significant

    Amylin analogues can increase hypoglycaemia risk when combined with insulin-stimulating agents.

  • GLP-1 receptor agonists (e.g. semaglutide in CagriSema combination)
    moderate

    The CagriSema combination is the primary clinical context for cagrilintide use. GI adverse events were more frequent in combination than either agent alone.

  • Oral medicines with narrow therapeutic index
    moderate

    Additive gastric-emptying slowing from amylin + GLP-1 dual mechanisms may alter absorption of orally administered drugs.

Storage and handling

As an investigational biologic, storage specifics are governed by the trial protocol or supplying pharmacy. Amylin analogues in this class are expected to require refrigeration at 2โ€“8ยฐC (36โ€“46ยฐF). Freezing typically destroys peptide biologics. Always follow the storage instructions provided by your trial site.

Research evidence

Published studies connected to this peptide with dosage and outcomes context.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide 4.5 mg with semaglutide 2.4 mg (CagriSema) in adults with overweight or obesity: a randomised, controlled, phase 1b trial

Human trial ยท 2021 ยท The Lancet ยท n=96 ยท Adults with overweight or obesity (BMI 27โ€“39.9) without type 2 diabetes

96 adults were randomised to once-weekly cagrilintide 4.5 mg alone, semaglutide 2.4 mg alone, CagriSema combination, or placebo for 20 weeks. Mean body-weight change was โˆ’15.6% with CagriSema versus โˆ’8.8% with semaglutide alone and โˆ’8.7% with cagrilintide alone โ€” suggesting additive effects of the combination.

Reported outcomes

  • weight_loss: Additive weight loss suggests complementary mechanisms โ€” amylin and GLP-1 pathways appear to act synergistically. (Secondary)
  • weight_loss: Mean body-weight change of โˆ’15.6% with CagriSema versus โˆ’8.8% with semaglutide alone and โˆ’8.7% with cagrilintide alone at 20 weeks. (Primary outcome)

Reported dosage

  • 4.5 mg ยท once weekly subcutaneous ยท 20 weeks โ€” Combined with semaglutide 2.4 mg in the CagriSema arm of the Phase 1b trial.
DOI: 10.1016/S0140-6736(21)01609-5 โ†—

Get the full companion experience in Viora

Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.

Available on iOS and Android.